Presentation is loading. Please wait.

Presentation is loading. Please wait.

McKesson (MCK) Healthcare Group.

Similar presentations


Presentation on theme: "McKesson (MCK) Healthcare Group."— Presentation transcript:

1 McKesson (MCK) Healthcare Group

2 McKesson Distributor Provide PHARMACEUTICALS, MEDICAL SUPPLIES and INFORMATION TECHNOLOGIES Distribution Solutions Technology Solutions

3 Summary Industry Outlook Two segments of Company
Customers and Suppliers Third Quarter Results Competitors Downsides Increasing Shareholder Value

4 Healthcare Portfolio Safer Play compared to riskier companies in the portfolio Distribution and Technology Celgene has a ton of upside but also a lot of downside Cerner does much of the same thing as MCK’s technology sector. EHR ect. Cerner has been doing well and we have seen a 60% rise since we bought it! (might want to analyze that to sell at a high?!) ALSO especially since the healthcare market in general is so prone to regulatory changes which we cannot predict/control, we felt it was a good idea to buy a company that has very little downside. Biopharmaceuticals Healthcare Providers

5 Industry Outlook WHOLESALE DRUG INDUSTRY OUTLOOK
Affordable Care Act increases the number of Americans covered by 32 million Increased technology and communication allows the medical industry to better respond to consumers wants and needs Specialty drugs (cancer, arthritis, etc) continue to have high profits TECHNOLOGY INDUSTRY OUTLOOK Overall positive outlook Technology companies should hoard cash because they will need it to invest Price fixing – largest competitor – AmerisourceBergen – has also been held responsible for price fixing. It is part of the industry, not a long term problem that will influence MCK’s sales and values. WHOLESALE DRUG INDUSTRY OUTLOOK Overall neutral outlook: increased demand for generics, etc but troubles concerning price fixing and general economic environment Increased demand for generic drugs, medical supplies and technology Affordable care act increases the number of Americans covered by 32 million; these people will be demanding medical products US population is aging, which means greater demand for drugs Increased technology and communication allows the medical industry to better respond to consumers wants and needs Specialty drugs (cancer, arthritis, etc) continue to have high profits Generics medications are the wave of the future; consumers don’t want to pay more than necessary TECHNOLOGY INDUSTRY OUTLOOK Overall positive outlook Vice Chair of Deloitte says number one challenge is economy – economy is improving Technology companies should hoard cash because they will need it to invest - McKesson has LOTS of cash Affordable Care Act and the digitalization of medical records is a huge expansion opportunity for McKesson – they administer a large proportion of this technology

6 Current price: $106.83 52 week range: $84.65 - $111.55 Beta: .63
Market cap: $24.88 billion Fell in 2008 and 2012 following elections, like most other stocks December 2012 – received a $2.61 B defense contract September 2012 – Arizona sues over price fixing Current price: $107.42 52 week range: $ $111.55 Beta: .63 Market cap: $24.88 billion

7 Distributions Solutions (MDS)
Largest pharmaceutical distributor in the world Distributes: Drugs Medical-surgical supplies Medical equipment Health and beauty care products Sells Pharmacy Software Fragmented market →ONE STOP SHOP Distributes ethical and proprietary drugs, medical-surgical supplies and equipment, and health and beauty care products throughout North America as well as providing specialty pharmaceutical solutions for biotech and pharmaceutical manufacturers, sells pharmacy software and provides consulting, outsourcing and other services. McKesson also operates McKesson Canada and has a 49% interest in Nadro, S.A. de C.V. (“Nadro”), one of the leading pharmaceutical distributors in Mexico. MDS revenues were up 1% in the third quarter of fiscal year ’13 driven mainly by growth in their U.S. pharmaceutical direct distribution and services business and growth in their Medical-Surgical distribution business. Healthcare is a fragmented market, therefore MDS’ “one stop shop” gives them an edge over competitors such as Cardinal Health and AmeriSource. Operates in Canada and has 49% interest in Nadro, a leading pharmaceutical distributors in Mexico. “Our full year view of the operating performance in our Distribution Solutions segment is now better than our original expectations, and our full year view of the operating performance in the primary businesses in Technology Solution remains unchanged,” said John H. Hammergren, chairman and chief executive officer. “This operating strength is offset by the charge in our Canadian business and revenue deferral in our international technology business, and as a result we are updating our previous outlook for the fiscal year and now expect Adjusted Earnings per diluted share of $7.10 to $7.30 for the fiscal year ending March 31, 2013.”

8 Growth Opportunities Increase in Drug Distribution Volume Negatives
New Customers Increased business with existing customers Negatives Faces strong competition in price Loss of one large customer → large revenue swings Lower-margin business than technology . There are also estimated gains for medical-surgical, reflecting higher private label sales. Negatives Low-margin business. Faces strong competition in price and service which may erode their profit. -Loss of any one large customer could lead to large revenue swings. LOWER MARGIN BUSINESS THAN TECHNOLOGY: MDS is moving towards a fee-based approach which will have a positive effect on predictability and a negative effect on profitability. Distribution agreements between distributors and most drug makers have over the years transitioned toward a more fee-based approach, with the distributors appropriately and predictably compensated for distribution. This has helped drug distributors by allowing them to reduce inventory levels. By holding less inventory, working capital requirements have declined, yielding higher operating cash flows. This will help aid the predictability of gross margins but not profitability. For profitability, they will look more towards McKesson Technology Solutions business.

9 Customers Top 10 customers accounted for 52% of total revenues
During 2012, sales to McKesson’s top ten customers accounted for approximately 52% of their total consolidated revenues. Sales to their two largest customers, CVS Caremark Corporation (“CVS”) and Rite Aid Corporation (“Rite Aid”), accounted for approximately 16% and 10% of our total consolidated revenues. Although CVS and Rite Aid are a large percentage, that is pretty normal for this market and nothing to be alarmed about. Obviously a loss of any of their customers would negatively affect their revenue streams but we don’t think they are overweight in CVS and Rite Aid. Below is great information, but might be too much info to share? Great in case they ask a question At March 31, 2012, accounts receivable from their ten largest customers were approximately 49% of total accounts receivable. Accounts receivable from CVS, Wal-Mart Stores, Inc. (“Walmart”) and Rite Aid were approximately 17%, 10% and 9% of total accounts receivable. Top 10 customers accounted for 52% of total revenues CVS: 16% Rite Aid: 10%

10 Suppliers Top ten suppliers account for 45% of purchases
No supplier accounted for more than 6% of total purchases Negative: Increased consolidation of pharmaceutical suppliers Suppliers: We obtain pharmaceutical and other products from manufacturers, none of which accounted for more than approximately 6% of our purchases in The loss of a supplier could adversely affect our business if alternate sources of supply are unavailable. We believe that our relationships with our suppliers, on the whole, are good. The ten largest suppliers in 2012 accounted for approximately 45% of our purchases. In recent years, pharmaceutical suppliers have been subject to increasing consolidation. As a result, a small number of very large companies control a significant share of the market. Accordingly, we depend on fewer suppliers for our products and therefore we may be less able to negotiate price terms with suppliers.

11 Research and Development
Research and Development: Our development expenditures primarily consist of our investment in software held for sale. We spent $487 million, $471 million and $451 million for development activities in 2012, 2011 and 2010 and of these amounts, we capitalized 10%, 14% and 17%. Development expenditures are primarily incurred by our Technology Solutions segment. Our Technology Solutions segment’s product development efforts apply computer technology and installation methodologies to specific information processing needs of hospitals and other customers. We believe that a substantial and sustained commitment to such expenditures is important to the long- term success of this business.

12 McKesson Technology Solutions
No. 1 in medical management software and services to Payers Serve 52% of all U.S. hospitals 77% with 200 or more bed Top competitors: AmerisourceBergen Corp., Epic, Cerner Corp., Athenahealth Inc., Allscripts Healthcare Solutions Inc. I deleted “3 percent of revenues because you can see it in the pie chart and you can just say it” MTS delivers enterprise-wide patient care, clinical, financial, supply chain and strategic management software solutions, pharmacy automation for hospitals, as well as connectivity, outsourcing and other services, to health care organizations in N. America, the U.K., and other European countries. Diversified technology segment positioned for stead long-term growth 200,000+ physician customers 1,000+ health care facilities using analytics Revenues of the Technology Solutions unit should rise as consultations with hospitals on electronic health record systems translate into bookings Stated that the freed up cash is most likely to be invested in higher-margined MTS segment. Competes with other computer services firms, consulting firms, shared service vendors, certain hospitals and hospital groups, hardware vendors and Internet-based companies with technology applicable to the health care industry. Supplied more than 50% of all U.S. hospitals, but 77% of those with 200 or more beds, large hospitals. Note on revenues: third quarter results reported that Technology Solutions were flat compared to prior year because of deferral in international business. Competitor news: last five companies are forming a nonprofit group aimed at setting standards for exchanging data across their systems. Competitive strengths include: geographical coverage, the scope and breadth of products and services, and it ability to offer package deals that include pharmaceutical and medical-surgical supplies. AmerisourceBergen: a pharmaceutical services company, provides drug distribution and related healthcare services and solutions to pharmacy, physician, and manufacturer customers primarily in the United States and Canada. Epic: private company develops and markets software for mid-size and large medical groups, hospitals, and integrated healthcare organizations. Cerner Corp: designs, develops, markets, installs, hosts, and supports healthcare information technology, healthcare devices, hardware, and content solutions for health care organizations and consumers worldwide. Athenahealth: provides physician practices with online practice management and electronic medical record services, combined with medical billing and other healthcare business services. Allscripts: provides physician practices, hospitals, and other healthcare providers with practice management and electronic health record technology, including electronic prescribing, care management, and revenue cycle software.

13 Healthcare IT Market Growth
Public policy agenda: ACA $17 billion in subsidies for hospitals that implement EMR 2015: penalties for hospitals without EMR Public policy agenda: Affordable Care Act stimulus package $17 billion in subsidies for hospitals that implement EMR 2015 penalties for hospitals without EMR Market growth Source:

14 Third Quarter Results Revenues of $31.2 billion, up 1%
Third Quarter GAAP earnings per diluted share of $1.24, up 3% Cash generation of $276 million, ended quarter with $2.7 billion Distributions Solutions Revenues up 1% Medical-Surgical distribution and services up 15%

15 Steady Revenue Growth Compound annual growth rate (CAGR) is an average growth rate over a period of several years. It is a geometric average of annual growth rates: CAGR = (ending value ÷starting value)1/(number of years - 1

16 Technology Solutions revenues increased in 2012 compared to 2011 primarily due to higher revenues for claims processing, increased revenues associated with the sale and installation of our software products, an increase in maintenance revenues from new and existing customers and a number of small acquisitions made during 2012.

17 Adjusted Earnings Per Share Growth

18 MCK vs. Competitors Ratios
Ticker MKT Cap P/E EPS 1 YR Growth Total Revenue Rev 1 YR Growth Op Margin ROE EV/EBITDA MCK 24.88B 16.55 30.4% 123.53B 9.5% 1.87% 19.97% 8.51 ABC 11.99B 17.77 9.8% 80.76B -0.6% 1.63% 27.01% 9.09 CAH 14.47B 12.45 11.9% 104.80B 4.8% 1.73% 17.68% 6.50 OMI 2.02B 17.03 -5.5% 8.91B 3.25% 2.32% 11.53% 8.07 Industry Median 9.39B 17.57 9.80% 26.08B 4.78% 13.46% 8.70 Data from Bloomberg

19 Why MCK over its Competitors
Size: Dominant Market Share in a highly competitive industry Strong Growth Fair relative valuation

20 Downsides Reliance on major accounts
Risks associated with integration of acquisitions Lower than expected drug price increases Lawsuits Generic Risks of potential policy changes In addition, we distribute generic pharmaceuticals, which can be subject to both price deflation and price inflation. Healthcare and public policy trends indicate that the number of generic drugs will increase next year as a result of the expiration of certain drug patents. In recent years, our financial results have improved from our generic drug offerings combined with an increase in the number of generic drug formularies available in the marketplace. Changes in the availability, pricing trends or reimbursement of these generic drugs, or changes in the rate of increase in the number of generic drugs, could have a material adverse impact on our results of operations.

21 Create Shareholder Value
$11 Billion of Capital Deployed from FY09- FY12 Value Creating Acquisitions Share Repurchases Internal Capital Spending Dividend

22 Acquisitions PSS World Medical October 2012 $2.1 billion transaction
Forecast $100M in cost synergies by year 4 Expect to add $0.15-$0.25 to Earnings per Share “Extensive distribution capabilities, deep product and technology expertise, and a broad portfolio of business services to an expanding industry” PSS World Medical: distributor of medical supplies to office based physicians, announced October , completed February 2013 for a purchase price of approx. $2.1 billion. PSSI has sales of $2.1B in the laboratory and private label markets. Expect the debt financed deal to add $0.15-$0.25 to MCK's EPS in year one after closing, with accretion rising significantly in the ensuing years. MCK forecasts $100M in cost synergies by year 4 (In the context of mergers, cost synergy is the savings in operating costs expected after two companies that compliment each other's strengths join). Combining PSS Medical with McKesson’s Medical Surgical supply American distributor of medical products, equipment, billing services and pharmaceutical related products to non-hospital healthcare providers.

23 Acquisitions Nov 2010 – US Oncology Jan 2012 – Katz Group
$2.16 B - cash Jan 2012 – Katz Group Canada $920 M - cash Integrated retail pharmacy network in Canada Expect EPS accretion of $0.15 in FY 13 US Oncology in December 2010 for $2.1 Billion cash. US Oncology is a leading provider of products and services to oncologists US Oncology, a leading integrated oncology company that serves one of the nation’s largest networks of community-based oncologists. US Oncology currently distributes ~$2.4 billion worth of oncology pharmaceuticals annually, operates 83 comprehensive cancer centers, offers practice management services to practices, and has a network of ~1,300 affiliated physicians. Management estimates U.S. Oncology currently serves ~17% of all domestic cancer patients Katz Group and Medicine Shoppe: Canadian drug distribution operations→ expect EPS accretion of $0.15 in FY 13 “This acquisition is a great example of using the strength of our balance sheet to reinforce the value we bring to our customers, while creating value for our shareholders.”

24 Valuation 20%/ 11 or 12%

25 Valuation (Mean)

26 Conclusion Key Investment Risks Strengths
Liable to lawsuits and government regulation Strengths One Stop Shop Size gives it competitive edge Evolving Healthcare IT Market Commitment to increasing Shareholder Value Cash Fits well into the Portfolio


Download ppt "McKesson (MCK) Healthcare Group."

Similar presentations


Ads by Google